We have previously shown that the HIV protease inhibitor lopinavir has selective toxicity against human papillomavirus (HPV)-positive cervical carcinoma cells via an unknown mechanism.
Methods
SiHa cervical carcinoma cells were stably transfected with the proteasome sensor vector pZsPro-Sensor-1 to confirm lopinavir inhibits the proteasome in these cells. The Panorama Xpress profiler 725 antibody array was then used to analyse specific changes in protein expression in lopinavir-treated versus control untreated SiHa cells followed by PCR and western blotting. Colorimetric growth assays of lopinavir-treated E6/E7 immortalised versus control human keratino-cytes were performed. Targeted small interfering RNA gene silencing followed by growth assay comparison of lopinavir- treated/untreated SiHa cells was also used.
Results
Lopinavir induced an increase in the fluorescence of pZsProSensor-1 transfected SiHa cells, indicative of proteasomal inhibition. Ribonuclease L (RNASEL) protein was shown to be up-regulated in lopinavir-treated SiHa cells, which was confirmed by PCR and western blot. Targeted silencing of RNASEL reduced the sensitivity of SiHa cells to lopinavir. Selective toxicity against E6/E7 immortalised keratinocytes versus control cells was also seen with lopinavir and was associated with up-regulated RNASEL expression.
Conclusions
These data are consistent with the toxicity of lopinavir against HPV-positive cervical carcinoma cells being related to its ability to block viral proteasome activation and induce an up-regulation of the antiviral protein RNASEL. This is supported by the drug's selective toxicity and up-regulation of RNASEL in E6/E7 immortalised keratinocytes combined with the increased resistance to lopinavir observed in SiHa cells following silencing of RNASEL gene expression.
References
1.
zur HausenH.Papillomavirus infections – a major cause of human cancers. Biochim Biophys Acta1996; 1288: F55–F78.
2.
WalboomersJ.M., JacobsM.V., ManosM.M.Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol1999; 189: 12–19.
3.
CastellsaguéX.Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol2008; 110: S4–S7.
4.
MuñozN., BoschF.X., de SanjoseS.Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med2003; 348: 518–527.
5.
PetoJ., GilhamC., FletcherO., MatthewsF.E.The cervical cancer epidemic that screening has prevented in the UK. Lancet2004; 364: 249–256.
6.
EllerbrockT.V., ChiassonM.A., BushT.J.Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA2000; 283: 1031–1037.
7.
LimaM.I., TafuriA., AraujoA.C., de Miranda LimaL., MeloV.H.Cervical intraepithelial neoplasia recurrence after conization in HIV-positive and HIV-negative women. Int J Gynaecol Obstet2009; 104: 100–104.
8.
HeardI., PalefskyJ.M., KazatchkineM.D.The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther2004; 9: 13–22.
9.
WrightT.C.Jr., SubbaraoS., EllerbrockT.V.Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol2001; 184: 279–285.
10.
GarlandS.M., SmithJ.S.Human papillomavirus vaccines: current status and future prospects. Drugs2010; 70: 1079–1098.
11.
Ali-RisasiC., PraetM., Van RenterghemL.[Human papillomavirus genotype profile in Kinshasa, Democratic Republic of the Congo: implications for vaccination]. Med Trop (Mars)2008; 68: 617–620. French.
12.
McKenzieN.D., KobetzE.N., HnatyszynJ., TwiggsL.B., LucciJ.A.III. Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types. Gynecol Oncol2010; 116: 572–577.
13.
HampsonL., KitchenerH.C., HampsonI.N.Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther2006; 11: 813–825.
14.
KimD.H., JarvisR.M., XuY.Combining metabolic fingerprinting and footprinting to understand the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral drug lopinavir. Analyst2010; 135: 1235–1244.
15.
KimD.H., JarvisR.M., AllwoodJ.W.Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells. Anal Bioanal Chem2010; 398: 3051–3061.
16.
RichardC., LannerC., NaryzhnyS.N.The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer. Oncogene2010; 29: 3435–3445.
17.
BisbalC., SilvermanR.H.Diverse functions of RNase L and implications in pathology. Biochimie2007; 89: 789–798.
PiccininiM., RinaudoM.T., ChiapelloN.The human 26S proteasome is a target of antiretroviral agents. AIDS2002; 16: 693–700.
20.
KlingerP.P., SchubertU.The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy. Expert Rev Anti Infect Ther2005; 3: 61–79.
21.
PiccininiM., RinaudoM.T., AnselminoA.The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir Ther2005; 10: 215–223.
22.
ParkerR.A., FlintO.P., MulveyR.Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol2005; 67: 1909–1919.
23.
BanksL., PimD., ThomasM.Viruses and the 26S proteasome: hacking into destruction. Trends Biochem Sci2003; 28: 452–459.
TangG., PerngM.D., WilkS., QuinlanR., GoldmanJ.E.Oligomers of mutant glial fibrillary acidic protein (GFAP) inhibit the proteasome system in alexander disease astrocytes, and the small heat shock protein alphaB-crystallin reverses the inhibition. J Biol Chem2010; 285: 10527–10537.
26.
Chatr-aryamontriA., CeolA., PelusoD.VirusMINT: a viral protein interaction database. Nucleic Acids Res2009; 37: D669–D673.
27.
De VuystH., LilloF., BroutetN., SmithJ.S.HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev2008; 17: 545–554.
28.
KwaraA., DelongA., RezkN.Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis2008; 46: 719–725.
29.
Smith-McCuneK.K., ShiboskiS., ChirenjeM.Z.Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS ONE2010; 5: e10094.
30.
SmithJ.S., MosesS., HudgensM.G.Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. J Infect Dis2010; 201: 1677–1685.
